|
|
Article: Pfizer, Pharmacia Merger: Will It Help Or Hurt Biotech Sector?
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
With the completion of the Pfizer Inc.-Pharmacia Corp. merger, the question that rises to the surface is this: Now that a big fish swallowed a rival and got bigger, what happens to the rest of the school in the pharmaceutical pond?
Because Pfizer now has become a very big fish indeed. The combined company has 14 products that are leaders in their therapeutic category. Pfizer now has more than 400 projects in its discovery pipeline and is building the largest library of chemical compounds in the industry. In 2002, Pfizer and Pharmacia had a combined research and development budget of more than $7 billion. Pfizer plans to file 20 ...